^
Association details:
| Biomarker: | KIT K642E |
|---|---|
| Cancer: | Melanoma |
| Drug: | temozolomide (DNA synthesis inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
525 KIT mutation with a low MS4A1/CD20 expression is associated with poor prognosis in melanoma
Published date:
11/09/2020
Excerpt:
69-year-old male with initial diagnosis of stage III-B melanoma of the left thumb with local recurrence in the resection site and then lung metastases...He was found to have KIT mutation (exon 13K642EMT), and started on imatinib, but he continued to have progression. He was switched to temozolomide with no response.
DOI:
10.1136/jitc-2020-SITC2020.0525
